Drug
Telotristat clinical trials
Includes 23 studies of Telotristat ethyl.
- studies test it
- 24
- open now
- 0
- in phase 3
- 5
- first study started
- 2009
Studies by the year they started
24 studies that test it; most in 2014 (7)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 7 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 10
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 8
Lexicon Pharmaceuticals (13) · M.D. Anderson Cancer Center (2) · Ipsen (2) · Emory University (1) · Barbara Ann Karmanos Cancer Institute (1) · Lowell Anthony, MD (1) · TerSera Therapeutics LLC (1) · Chandrikha Chandrasekhara (1)
Often tested with
Tested in the same studies.
Omeprazole (1) · Famotidine (1) · Octreotide (1) · Fexofenadine (1) · Midazolam (1) · Retifanlimab (1)
Studies
Open first, then newest update. How each study uses telotristat is read from its arms, and is right about nine times in ten.
Testing it · 24
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine TumorActive, not recruitingPhase 3M.D. Anderson Cancer CenterNCT04810091Written as Telotristat Ethyl
- Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic CancerCompletedPhase 2Emory UniversityNCT03910387Written as Telotristat Ethyl
- AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine NeoplasmCompletedPhase 2Barbara Ann Karmanos Cancer InstituteNCT03453489Written as Telotristat Etiprate
- Telotristat With Lutathera in Neuroendocrine TumorsTerminatedPhase 2Lowell Anthony, MDNCT04543955Written as Telotristat (Low-Dose)
- A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract CancerTerminatedPhase 2TerSera Therapeutics LLCNCT03790111Written as telotristat ethyl
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat EthylWithdrawnPhase 2Chandrikha ChandrasekharaNCT04713202Written as Telotristat ethyl
- Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine TumorsWithdrawnPhase 2University of ChicagoNCT04672876Written as Telotristat Ethyl Oral Tablet
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnPhase 2M.D. Anderson Cancer CenterNCT04776876Written as Telotristat Ethyl
- Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal FunctionCompletedPhase 1IpsenNCT03442725Written as Telotristat etiprate
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWithdrawnPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT04065165Written as Telotristat Ethyl
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCompletedPhase 3Lexicon PharmaceuticalsNCT02026063Written as Telotristat etiprate
- A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative ColitisCompletedPhase 2Lexicon PharmaceuticalsNCT01456052Written as Telotristat Etiprate
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeCompletedPhase 2Lexicon PharmaceuticalsNCT01104415Written as Telotristat etiprate
- Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy SubjectsCompletedPhase 1IpsenNCT02683577Written as telotristat etiprate
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedPhase 2Lexicon PharmaceuticalsNCT00853047Written as Telotristat etiprate
- Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic ImpairmentCompletedPhase 1Lexicon PharmaceuticalsNCT03423446Written as Telotristat Ethyl
- A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy SubjectsCompletedPhase 1Lexicon PharmaceuticalsNCT03302845Written as Telotristat ethyl 250 mg
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedPhase 3Lexicon PharmaceuticalsNCT01677910Written as Telotristat etiprate
- Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedPhase 3Lexicon PharmaceuticalsNCT02063659Written as Telotristat etiprate
- Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy SubjectsCompletedPhase 1Lexicon PharmaceuticalsNCT02195635Written as Telotristat etiprate
Codes
What other systems call telotristat · ClinicalTrials.gg INT000100
- MeSH (NLM) C000592493telotristatOne source NLM
- UNII (FDA) 381V4FCV2ZTELOTRISTATConfirmed FDA, NLM, Wikidata
- RxNorm 1872382Confirmed FDA, Wikidata
- Wikidata Q27256725telotristatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152549TelotristatOne source FDA
- DrugBank DB14218One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592493 | telotristat | One source NLM |
| UNII (FDA) | 381V4FCV2Z | TELOTRISTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1872382 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27256725 | telotristat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152549 | Telotristat | One source FDA |
| DrugBank | DB14218 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.